• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Solventum Corporation

    5/30/25 4:09:35 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care
    Get the next $SOLV alert in real time by email
    SD 1 a2025formsd.htm SD Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM SD
    SPECIALIZED DISCLOSURE REPORT

    SOLVENTUM CORPORATION
    (Exact Name of Registrant as Specified in Its Charter)
    Delaware
    File No. 001-41968
    92-2008841
    (State or other jurisdiction of incorporation)
    (Commission File Number)
    (IRS Employer Identification No.)
    3M Center, Building 275-6W 2510 Conway Avenue East, Maplewood, Minnesota
    55144
    (Address of Principal Executive Offices)
    (Zip Code)

    Wayde McMillan, Executive Vice President and Chief Financial Officer (651) 733-1110
    (Name and telephone number, including area code, of the person to contact in connection with this report.)

    ☒
    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.
    ☐
    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended ___________.

    Section 1 — Conflict Minerals Disclosure

    Item 1.01 Conflict Minerals Disclosure and Report

    Conflict Minerals Disclosure

    This Specialized Disclosure Report (“Form SD”) for Solventum Corporation (“Solventum,” “Company,” “we,” “our”) is provided in accordance with Rule 13p-1 under the Securities Exchange Act of 1934 for the reporting period from January 1 to December 31, 2024. References to Solventum’s website are provided for convenience only, and its contents are not incorporated by reference into this Form SD or the attached Conflict Minerals Report, nor are they deemed filed with the U.S. Securities and Exchange Commission (“SEC”).

    “Conflict Minerals” are defined by the SEC as cassiterite, columbite-tantalite, wolframite and gold, and their derivatives, which are limited to tin, tantalum and tungsten (collectively “3TG”). During calendar year 2024, Solventum manufactured and contracted to manufacture products in which 3TG were necessary to the functionality or production of those products.

    A copy of Solventum’s Conflict Minerals Report is provided as Exhibit 1.01 hereto and details the reasonable country of origin inquiry and due diligence measures undertaken during the reporting period by the Company on a



    consolidated basis. A copy of the Conflict Minerals Report is also publicly available at https://investors.solventum.com/.

    Item 1.02 Exhibit

    The Conflict Minerals Report required by Item 1.01 is filed as Exhibit 1.01 to this Form SD.

    Section 3 — Exhibits

    Item 3.01 Exhibits

    Exhibit 1.01 — Solventum 2025 Conflict Minerals Report for the period from January 1 to December 31, 2024, as required by Items 1.01 and 1.02 of this Form SD.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.


    Solventum Corporation
    ___________________________________________
    (Registrant)

    /s/Marcela Kirberger                            May 30, 2025
    ___________________________________________             _______________________
    Chief Legal Affairs Officer                (Date)




    Get the next $SOLV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SOLV

    DatePrice TargetRatingAnalyst
    6/6/2025Sector Weight
    KeyBanc Capital Markets
    5/19/2025$87.00Neutral → Overweight
    Piper Sandler
    12/4/2024$70.00Neutral
    Mizuho
    10/8/2024$82.00Buy
    Stifel
    10/7/2024$71.00Neutral
    Piper Sandler
    9/26/2024Peer Perform
    Wolfe Research
    9/5/2024Neutral
    BTIG Research
    6/24/2024Hold
    Argus
    More analyst ratings

    $SOLV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Solventum Named a Best Company to Work for by U.S. News & World Report

      Recognized among the top 25 percent of companies in healthcare and research, and top 25 percent of companies in the Midwest in just 14 months as a new company Award highlights success in phase one of Solventum's three-phased Transformation Plan ST. PAUL, Minn., June 18, 2025  /PRNewswire/ -- Solventum (NYSE:SOLV), a global leader in innovative medical technology and solutions, today announced U.S. News & World Report has named the company among its 2025-2026 list of Best Companies to Work For, earning top honors in three categories: Best Companies OverallHealth Care and Resear

      6/18/25 10:00:00 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum to Participate in the 2025 Goldman Sachs Health Care Conference

      ST. PAUL, Minn., June 3, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today its executives will participate in a fireside chat at the Goldman Sachs 46th Annual Global Health Care Conference on Tuesday, June 10, 2025, beginning at approximately 4:00 p.m. EDT in Miami, FL. A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com. About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' tou

      6/3/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum Reports First Quarter 2025 Financial Results

      Reported sales increased 2.6%; organic sales increased 4.3%Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5%ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales increased 2.6% to $2.1 billion; up 4.3% on an organic basisGAAP diluted earnings per share of $0.78; adjusted diluted earnings per share of $1.34Operating cash flow of $29 million; free cash flow of $(80) million"Our first quarter fiscal year 2025 results reflect soli

      5/8/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    SEC Filings

    See more
    • SEC Form SD filed by Solventum Corporation

      SD - Solventum Corp (0001964738) (Filer)

      5/30/25 4:09:35 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Solventum Corporation

      10-Q - Solventum Corp (0001964738) (Filer)

      5/9/25 12:24:15 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Solventum Corp (0001964738) (Filer)

      5/8/25 4:13:51 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cox Carrie Smith converted options into 5,148 shares (SEC Form 4)

      4 - Solventum Corp (0001964738) (Issuer)

      5/15/25 4:23:40 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Hanson Bryan C converted options into 34,315 shares and covered exercise/tax liability with 13,503 shares, increasing direct ownership by 51% to 61,605 units (SEC Form 4)

      4 - Solventum Corp (0001964738) (Issuer)

      5/15/25 4:23:28 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Director Harris Bernard A Jr converted options into 3,564 shares (SEC Form 4)

      4 - Solventum Corp (0001964738) (Issuer)

      5/15/25 4:23:15 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • KeyBanc Capital Markets initiated coverage on Solventum Corporation

      KeyBanc Capital Markets initiated coverage of Solventum Corporation with a rating of Sector Weight

      6/6/25 8:37:20 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum Corporation upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Solventum Corporation from Neutral to Overweight and set a new price target of $87.00

      5/19/25 8:47:51 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Mizuho initiated coverage on Solventum Corporation with a new price target

      Mizuho initiated coverage of Solventum Corporation with a rating of Neutral and set a new price target of $70.00

      12/4/24 7:49:27 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    Leadership Updates

    Live Leadership Updates

    See more
    • Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors

      BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics. "We are thrilled to welcome Elizabeth to Ampersand's Board as we leverage our AND Platform to

      2/11/25 8:00:00 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing

      Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker BOSTON, Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Eliza

      1/8/25 6:30:00 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum Names Surgeon and Diagnostics Pioneer Dr. Ryan Egeland as Chief Medical Officer

      ST. PAUL, Minn., Oct. 10, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that Dr. Ryan Egeland, MD, has been named chief medical officer. Dr. Egeland is responsible for leading Solventum's Global Medical and Clinical Affairs team, amplifying the voice of clinicians and patients. In this role, he will focus on fostering industry collaboration and identifying innovation and market expansion opportunities at the intersection of scientific rigor, clinical need, and commercial practicality. Dr. Egeland will report to Chris Barry, executive vice president and group presi

      10/10/24 9:00:00 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Solventum Corporation

      SC 13G/A - Solventum Corp (0001964738) (Subject)

      11/12/24 5:47:11 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Solventum Corporation

      SC 13G/A - Solventum Corp (0001964738) (Subject)

      11/4/24 1:47:43 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care